Elanco Animal Health Stock (NYSE:ELAN)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$12.60

52W Range

$9.62 - $18.80

50D Avg

$14.09

200D Avg

$14.97

Market Cap

$6.21B

Avg Vol (3M)

$4.57M

Beta

1.40

Div Yield

-

ELAN Company Profile


Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Show More

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NYSE

ADR

-

Country

US

Employees

9,300

IPO Date

Sep 20, 2018

Website

ELAN Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 22Dec 21Dec 20
Swine$384.00M--
Poultry$716.00M--
Pet Health$2.14B$2.35B-
Farm Animal$2.22B$2.33B-
Contract Manufacturing$54.00M$82.00M$80.20M
Cattle$944.00M--
Farm Animal Future Protein And Health--$734.10M
Pet Health Therapeutics--$365.80M
Pet Health Disease Prevention--$992.70M
Farm Animal Ruminants And Swine--$1.10B

Fiscal year ends in Dec 23 | Currency in USD

ELAN Financial Summary


Dec 23Dec 22Dec 21
Revenue$4.42B$4.42B$4.76B
Operating Income$326.00M$358.00M$297.00M
Net Income$-1.23B$-74.00M$-472.00M
EBITDA$326.00M$886.00M$853.00M
Basic EPS$-2.50$-0.15$-0.97
Diluted EPS$-2.50$-0.15$-0.97

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q2 24Aug 08, 24 | 12:31 PM
Q1 24May 08, 24 | 12:00 AM
Q4 23Feb 26, 24 | 11:38 AM

Peer Comparison


TickerCompany
LNTHLantheus Holdings, Inc.
ITCIIntra-Cellular Therapies, Inc.
HLNHaleon plc
ESPREsperion Therapeutics, Inc.
PAHCPhibro Animal Health Corporation
VTRSViatris Inc.
IRWDIronwood Pharmaceuticals, Inc.
DCPHDeciphera Pharmaceuticals, Inc.
PBHPrestige Consumer Healthcare Inc.
TEVATeva Pharmaceutical Industries Limited
ALKSAlkermes plc
PCRXPacira BioSciences, Inc.
COLLCollegium Pharmaceutical, Inc.
CTLTCatalent, Inc.
SIGASIGA Technologies, Inc.